September 14, 2006 -- Biogen Idec will pay up to $37.5 mllion to in-license a pulmonary arterial hypertension drug from a Swiss biotech firm, mondoBIOTECH; Lilly and Amylin said their diabetes drug Byetta was just as effective as insulin in type 2 diabetes; MannKind enrolled 1800 patients in a test of its inhaled form of insulin; Genzyme released data from a halted Phase II trial of Campath; and Novartis published positive Phase II data on its investigational drug for multiple sclerosis. The Centient Biotech 200™ edged 2 points lower to 3715.49, a loss of .06%. More details...
